Published patient case reports have identified the CIC::LEUTX chimera to occur between CIC exon 20 and LEUTX exon 3 across the different cancers of renal sarcoma, spinal cord sarcoma, angiosarcoma, central nervous system embryonal tumors, and pediatric-type high-grade neuroepithelial tumors (Huang et al., 2016; Hu et al., 2020; Lake et al., 2020; Song et al., 2022; Sievers et al., 2023; Tang et al., 2023) (Figure 1). Here, LEUTX is linked to angiosarcoma.